Special Issue "Chimeric Antigen Receptor (CAR) T Cell Therapy"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 December 2017).
Interests: cancer biomarker; evidence-based medicine; extracellular vesicles; genomics; microRNA; molecular diagnostics; non-coding RNAs; nasopharyngeal carcinoma; next-generation sequencing; non-small cell lung cancer; proteomics; drug repurposing and bioinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Molecular Classification of Human Cancer: Diagnosis and Treatment
Special Issue in International Journal of Molecular Sciences: Liquid Biopsy for Clinical Application
Special Issue in International Journal of Molecular Sciences: Big Data for Oncology
Special Issue in International Journal of Molecular Sciences: Next-Generation Sequencing for Clinical Application
Special Issue in International Journal of Molecular Sciences: Molecular Classification of Human Cancer: Diagnosis and Treatment 2016
Topical Collection in International Journal of Molecular Sciences: Precision Medicine—From Bench to Bedside
Special Issue in International Journal of Molecular Sciences: Extracellular Vesicles: Biology and Potentials in Cancer Therapeutics
Cancer immunotherapy has generated tremendous excitement due to striking clinical outcomes seen in patients with chemotherapy-refractory cancers, such as lung cancer and acute leukemias. The two main cancer immunotherapies responsible for these successes are checkpoint blockade inhibitors and adoptive cell therapy with gene-engineered T cells. Both of these immunotherapies involve directing a patients T cells to their malignancy. This Special Issue will focus on adoptive T cell therapies and the chimeric antigen receptor (CAR), which genetically retargets the T cell to the patient’s cancer. The CAR includes an antigen-binding domain, derived from an antibody, hinge and transmembrane domains, and activation and costimulation domains derived from the T cell receptor. Over the past three decades, from the first description of the CAR, various groups have led the way with pre-clinical studies describing the biology of CAR T cells, as well as developing and validating their use for various malignancies. In the last several years, the efforts from these groups efforts have finally come to fruition with early and mid-stage clinical trials demonstrating outstanding clinical outcomes for pediatric and adult patients, with a heretofore fatal chemotherapy refractory disease, B-ALL. The results have been so disruptive to standard cancer therapies the first regulatory-approval for a gene-modified cell therapy for cancer is likely on the horizon. However, the clinical evaluation of this new therapy has also revealed a new set of immune-related toxicities that require careful management. In this Special Issue, we have compiled a set of articles to review pre-clinical CAR design and optimization, clinical application, CAR T cell toxicities, GMP CAR T cell production and QC/QA, as well as future pre-clinical and clinical directions.
Dr. William Chi-shing Cho
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- adoptive T cell therapy
- chimeric antigen receptors
- cancer immunology
- gene therapy